Skip to main content

Table 6 Association of candidate variants

From: Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

Measurement SNP/HLA allele First publication Published effect direction OR/β (pooled) p(one-sided) (all prep.) p(one-sided) (IFNβ-1a s.c.) p(one-sided) (IFNβ-1b s.c.)
nADA presence rs2454138-A [15] risk 1.40OR 1.59 × 10−05 9.65 × 10−01 2.41 × 10−16
nADA presence rs522308-T [15] risk 1.39OR 2.06 × 10−05 9.80 × 10−01 8.76 × 10−17
nADA presence rs9272105-A [14] protective 0.62OR 1.21 × 10−13 2.76 × 10−12 1.14 × 10−05
nADA presence HLA-DQA1*02:01 [16] risk 1.27OR 2.12 × 10−02 5.74 × 10−01 2.99 × 10−04
nADA presence HLA-DRB1*04:01 [12] risk 1.76OR 9.46 × 10−06 8.71 × 10−01 1.62 × 10−19
nADA titer HLA-DRB1*04:08 [12] risk 1.14β 7.50 × 10−09 1.56 × 10−05 6.21 × 10−05
nADA titer in nADA-positive HLA-DRB1*04:08 [12] risk 0.48β 2.32 × 10−03 2.45 × 10−02 3.59 × 10−04
nADA presence HLA-DRB1*07:01 [10] risk 1.28OR 1.90 × 10−02 5.47 × 10−01 3.03 × 10−04
nADA presence HLA-DRB1*08:01 [13] risk 1.38OR 2.52 × 10−02 1.66 × 10−05 9.14 × 10−01
nADA presence HLA-DRB1*15:01 [13] risk 1.32OR 6.27 × 10−05 4.24 × 10−19 1.00 × 100
bADA levels HLA-DRB1*16:01 [11] risk 0.54β 7.10 × 10−06 1.12 × 10−02 3.34 × 10−05
nADA titer in nADA-positive HLA-DRB1*16:01 [11] risk 0.62β 2.11 × 10−04 2.93 × 10−01 5.07 × 10−05
nADA presence HLA-DQA1*05:01 [13] / [16] protective 0.68OR 3.09 × 10−07 3.15 × 10−09 4.59 × 10−03
nADA presence HLA-DQB1*02:01 [16] protective 0.65OR 6.24 × 10−06 1.46 × 10−09 1.94 × 10−01
nADA presence HLA-DRB1*03:01 [11] / [16] protective 0.65OR 5.43 × 10−06 1.55 × 10−09 1.83 × 10−01
nADA presence HLA-DRB1*04:04 [11] protective 0.56OR 2.29 × 10−03 6.91 × 10−03 1.03 × 10−01
  1. The table shows previously published SNPs and HLA alleles that showed a one-sided p < 2.5 × 10−3 (Bonferroni correction for 20 tests) either in the pooled analysis across treatment preparations or in the analysis of IFNβ-1a s.c.-treated or IFNβ-1b s.c.- treated patients. P values below this threshold are labeled in bold font. For nADA presence, odds ratios are provided (marked by OR), and for quantitative ADA measures effect sizes (marked by β), both refer to the pooled analysis across treatment preparations. For a detailed table of all results, see Additional file 23. β effect size; OR odds ratio; prep treatment preparations. “nADA titer in nADA-positive” refers to an analysis of nADA titers restricted to nADA-positive patients